Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating

Eupraxia Pharmaceuticals (EPRX) has received a new Buy rating, initiated by William Blair analyst, Lachlan Hanbury Brown.

Lachlan Hanbury Brown has given his Buy rating due to a combination of factors, primarily the differentiated drug-delivery platform Eupraxia is advancing in eosinophilic esophagitis. He highlights EP-104GI’s ability to sustain therapeutic steroid levels directly at the disease site with limited systemic exposure, which could deliver durable benefit with as infrequent as once-yearly dosing and an attractive safety profile.

He also points to the sizable and under-served EoE market, with hundreds of thousands of U.S. patients and few effective options, supporting his view that EP-104GI could reach substantial peak sales if successful. In addition, the potential to expand the same technology into further gastrointestinal indications, alongside prior validation of the EP-104 platform in osteoarthritis, reinforces his conviction despite customary clinical and competitive risks for a development-stage biotech company.

In another report released on March 21, LifeSci Capital also maintained a Buy rating on the stock with a $16.00 price target.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.